Nitrogen Of The Hetero Ring Is Shared By An Additional Cyclo Of The Polycyclo Ring System Patents (Class 540/579)
-
Patent number: 11396511Abstract: The present invention relates to compounds of [Formula A]: including N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide, 2-((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)carbamoyl)phenyl acetate, methods for preparing the compounds, and compositions including the compounds as active ingredients. The compounds of the present invention are very effective in anti-inflammation and pain relief. The compositions of the present invention are effective in preventing or treating inflammation and/or pain.Type: GrantFiled: December 11, 2018Date of Patent: July 26, 2022Assignee: FRONTBIO CO., LTD.Inventors: Hong Won Suh, Jae Yong Lee, Soon Sung Lim, Jeong Tae Lee, Seung Hwan Hwang, Sang Pil Jang, Sung Hwan Park, Jeong Ho Jeon, Hyun Min Lim, Ju Mi Lee
-
Patent number: 10968228Abstract: The invention provides novel methods for preparing indolinobenzodiazepine monomer compounds of formula (I) below and their synthetic precursors:Type: GrantFiled: September 4, 2019Date of Patent: April 6, 2021Assignee: IMMUNOGEN, INC.Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
-
Patent number: 9822117Abstract: The present invention discloses pyridoindolobenz[b,d]azepines compositions of Formula 1, wherein Y is a single bond or a double bond. A and B are independently —(CH2)n—; and ‘n’ varies from 0 to 3. R1 to R10 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.Type: GrantFiled: March 2, 2014Date of Patent: November 21, 2017Assignee: DAYA DRUG DISCOVERIES, INC.Inventor: Parthasarathi Rajagopalan
-
Patent number: 9682984Abstract: The invention relates to new and improved processes for the preparation of Alcaftadine and pharmaceutically acceptable salts thereof as well as an intermediate for the preparation of Alcaftadine. The new process saves a number of steps compared to the known process and results in a higher yield.Type: GrantFiled: March 24, 2014Date of Patent: June 20, 2017Assignee: Crystal Pharma S.A.U.Inventors: Antonio Lorente Bonde-Larsen, Jesús Miguel Iglesias Retuerto, Franciso Javiér Gallo Nieto, Juan José Ferreiro Gil
-
Patent number: 9617274Abstract: Synthetic noribogaine preferably free of ibogaine and, optionally, one or more of other naturally occurring Tabernanth iboga alkaloids, is provided.Type: GrantFiled: March 2, 2015Date of Patent: April 11, 2017Assignee: DEMERX, INC.Inventors: Robert M. Moriarty, Richard D. Gless, Jr.
-
Patent number: 9580436Abstract: The present invention relates to an improved process of preparing substantially pure alcaftadine comprising reacting substantially pure compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to obtain alcaftadine:Type: GrantFiled: November 18, 2015Date of Patent: February 28, 2017Assignee: ENALTEC LABS PRIVATE LIMITEDInventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
-
Patent number: 9469649Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.Type: GrantFiled: October 3, 2014Date of Patent: October 18, 2016Assignee: DEMERX, INC.Inventor: Robert M. Moriarty
-
Patent number: 9403837Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.Type: GrantFiled: September 15, 2014Date of Patent: August 2, 2016Assignee: DEMERX, INC.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Patent number: 9403817Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: October 14, 2014Date of Patent: August 2, 2016Assignee: DEMERX, INC.Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, Jr.
-
Patent number: 9255105Abstract: The present invention is related to a substantially pure compound of structural formula (VIII), a process for the purification of a compound of structural formula (VIII) and an improved process of preparing an alcaftadine compound of structural formula (I).Type: GrantFiled: November 19, 2013Date of Patent: February 9, 2016Assignee: ENALTEC LABS PRIVATE LIMITEDInventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
-
Patent number: 9150584Abstract: Provided herein are indole and benzofuran fused isoquinuclidene derivatives. Also provided herein are processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (?) and (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms.Type: GrantFiled: January 24, 2013Date of Patent: October 6, 2015Assignee: DEMERX, INC.Inventor: Robert M. Moriarty
-
Patent number: 9040519Abstract: This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.Type: GrantFiled: February 18, 2011Date of Patent: May 26, 2015Assignee: Medivation Technologies, Inc.Inventors: Sarvajit Chakravarty, Barry Patrick Hart, Rajendra Parasmal Jain
-
Patent number: 9040520Abstract: Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.Type: GrantFiled: September 14, 2012Date of Patent: May 26, 2015Assignee: DemeRx, Inc.Inventors: Richard D. Gless, Jr., William C. Schinzer
-
Publication number: 20150140489Abstract: Disclosed and claimed herein is a composition of matter having a general structure chosen from (I), (II), (III) or (IV); wherein X and Y are the same or different, wherein at least one of X and Y comprises an acid labile group, wherein R1 is a saturated or unsaturated group having from 1-4 carbon atoms, R2 is chosen from hydrogen or a saturated or unsaturated group having from 1-4 carbon atoms, R3 is a saturated or unsaturated group having from 1-4 carbon atoms, and R4 is a saturated or unsaturated group having from 1-4 carbon atoms.Type: ApplicationFiled: October 21, 2014Publication date: May 21, 2015Inventors: Alex Philip Graham Robinson, Dongxu Yang, Andreas Frommhold, Thomas Lada, John L. Roth, Xiang Xue
-
Publication number: 20150133655Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.Type: ApplicationFiled: October 14, 2014Publication date: May 14, 2015Applicant: DEMERX, INC.Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, JR.
-
Publication number: 20150119570Abstract: The present invention is related to pure compound of structural formula (VIII), process for the purification of compound of structural formula (VIII) and improved process of preparing alcaftadine compound of structural formula (I).Type: ApplicationFiled: November 19, 2013Publication date: April 30, 2015Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
-
Publication number: 20150094466Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.Type: ApplicationFiled: October 3, 2014Publication date: April 2, 2015Applicant: DemeRx, Inc.Inventor: Robert M. Moriarty
-
Publication number: 20150087633Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.Type: ApplicationFiled: December 1, 2014Publication date: March 26, 2015Applicant: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Donald D. Payan, Sylvia Braselmann
-
Patent number: 8946206Abstract: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.Type: GrantFiled: December 15, 2011Date of Patent: February 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Craig C. Garner, H. Craig Heller, Damien Colas, Daniel Z. Wetmore
-
Patent number: 8940728Abstract: This invention relates noribogaine derivatives, compositions and methods of use thereof.Type: GrantFiled: January 2, 2013Date of Patent: January 27, 2015Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr., Robert M. Moriarty
-
Patent number: 8937061Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.Type: GrantFiled: December 7, 2012Date of Patent: January 20, 2015Assignee: DemeRx, Inc.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Publication number: 20150005492Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.Type: ApplicationFiled: September 15, 2014Publication date: January 1, 2015Applicant: DEMERX, INC.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Publication number: 20140357741Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR.
-
Publication number: 20140357621Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Applicant: Novartis AGInventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
-
Publication number: 20140349992Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: ApplicationFiled: June 9, 2014Publication date: November 27, 2014Applicant: Sunovion Pharmaceuticals Inc.Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Patent number: 8877921Abstract: Synthetic voacangine, including in substantially enantiomerically enriched forms, and derivatives thereof are provided.Type: GrantFiled: January 24, 2013Date of Patent: November 4, 2014Assignee: DemeRx, Inc.Inventor: Robert M. Moriarty
-
Publication number: 20140315837Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Deborah C. Mash, Richard D. Gless
-
Publication number: 20140315891Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.Type: ApplicationFiled: April 21, 2014Publication date: October 23, 2014Inventor: Deborah C. Mash
-
Patent number: 8859764Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: January 23, 2012Date of Patent: October 14, 2014Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, Jr.
-
Publication number: 20140303144Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: ApplicationFiled: February 17, 2012Publication date: October 9, 2014Applicant: Medivation Technologies, Inc.Inventors: Andrew Asher Protter, Sarvajit Chakravarty
-
Patent number: 8853201Abstract: Disclosed herein are sulfate esters of noribogaine or 9,17 dihydronoribogaine, and pharmaceutically acceptable salts of each thereof, pharmaceutical compositions comprising such compounds, and methods of their use, including in treating addiction and/or pain.Type: GrantFiled: December 7, 2012Date of Patent: October 7, 2014Assignee: DemeRx, Inc.Inventors: Richard D. Gless, Jr., Robert M. Moriarty
-
Publication number: 20140294805Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.Type: ApplicationFiled: September 2, 2011Publication date: October 2, 2014Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
-
Publication number: 20140296209Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: ApplicationFiled: February 17, 2012Publication date: October 2, 2014Applicant: MEDIVATION TECHNOLOGIES, INC.Inventors: Andrew Asher Protter, Sarvajit Chakravarty
-
Patent number: 8846659Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.Type: GrantFiled: December 7, 2011Date of Patent: September 30, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Kevin Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, Michael A. Walker
-
Publication number: 20140255386Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.Type: ApplicationFiled: July 24, 2012Publication date: September 11, 2014Applicants: NORTH CAROLINA STATE UNIVERSITY, THE WISTAR INSTITUTEInventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
-
Patent number: 8802832Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: GrantFiled: August 4, 2011Date of Patent: August 12, 2014Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr.
-
Patent number: 8796260Abstract: Compounds of Formula I: I (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.Type: GrantFiled: February 6, 2009Date of Patent: August 5, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Howard G. Selnick, Ian M. Bell
-
Publication number: 20140200209Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicants: ViiV Healthcare Company, Shionogi & Co., Ltd.Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
-
Patent number: 8772301Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: GrantFiled: December 17, 2010Date of Patent: July 8, 2014Assignee: Sunovion Pharmaceuticals, Inc.Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
-
Publication number: 20140187655Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.Type: ApplicationFiled: May 10, 2011Publication date: July 3, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR.
-
Patent number: 8765737Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: May 10, 2011Date of Patent: July 1, 2014Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr.
-
Publication number: 20140179682Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: ApplicationFiled: June 8, 2012Publication date: June 26, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Patent number: 8742096Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: March 14, 2012Date of Patent: June 3, 2014Assignee: DemeRx, Inc.Inventors: Robert M. Moriarty, Simon Mbua Ngale Efange
-
Patent number: 8741891Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.Type: GrantFiled: June 21, 2011Date of Patent: June 3, 2014Assignee: DemeRx, Inc.Inventor: Deborah C. Mash
-
Publication number: 20140120013Abstract: One aspect of the present invention relates to salts that are room-temperature ionic liquids (RTILs), methods of making them, and methods of using them in connection with temporary or permanent gas sequestration. Another aspect of the present invention relates to a class of solvents which can be transformed into RTILs by exposure to a gas, and methods of using them in connection with temporary or permanent gas sequestration.Type: ApplicationFiled: November 5, 2013Publication date: May 1, 2014Applicant: Georgetown UniversityInventors: Tao Yu, Richard G. Weiss, Taisuke Yamada, Mathew George
-
Publication number: 20140113878Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: ApplicationFiled: August 4, 2011Publication date: April 24, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR.
-
Patent number: 8703103Abstract: Sterically hindered imidazole ligands are described, along with their synthesis, which are capable of coordinating to Group 2 metals, such as: calcium, magnesium, strontium, in an eta-5 coordination mode which permits the formation of monomeric or dimeric volatile complexes. A compound comprising one or more polysubstituted imidazolate anions coordinated to a metal selected from the group consisting of barium, strontium, magnesium, radium or calcium or mixtures thereof. Alternatively, one anion can be substituted with and a second non-imidazolate anion. Synthesis of the novel compounds and their use to form BST films is also contemplated.Type: GrantFiled: January 28, 2011Date of Patent: April 22, 2014Assignee: Air Products and Chemicals, Inc.Inventors: John Anthony Thomas Norman, Melanie K. Perez, Moo-Sung Kim
-
Publication number: 20140107102Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 8, 2013Publication date: April 17, 2014Applicant: Allergan, Inc.Inventors: Jagdish Parasrampuria, Avner Ingerman, Frans Janssens, Anton Megens
-
Publication number: 20140088085Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.Type: ApplicationFiled: January 12, 2012Publication date: March 27, 2014Applicants: ARRAY BIOPHARMA, INC, VENTIRX PHARMACEUTICALS, INCInventors: Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones, James Jeffry Howbert, Robert Hershberg, Joseph P. Lyssikatos, Hong Woon Yang
-
Publication number: 20140039182Abstract: The present invention relates to compositions, for example, the DBU/Hexafluoroacetone hydrate salt, and processes of preparing and using the same for the modification of chemical compounds via the release of trifluoroacetate. The DBU/Hexafluoroacetone hydrate salt can perform trifluoromethylation reactions on chemical compounds, such as carbonyl group-containing compounds.Type: ApplicationFiled: March 22, 2012Publication date: February 6, 2014Inventors: David A. Colby, Mark V. Riofski, Changho Han